Pharvaris

As the year comes to an end, we are taking time to reflect on the strides we have made in advancing #deucrictibant, our investigational treatment for #HereditaryAngioedema. None of these achievements would have been possible without the support of the #HAECommunity. We are excited to carry this momentum forward into 2025. This post relates to ongoing investigational studies. Safety and efficacy have not been established and approval is not guaranteed.

#HereditaryAngioedema attacks can be severe and unpredictable. We aspire to empower patient choice and address unmet needs. Pharvaris is dedicated to developing #deucrictibant, a potential new treatment for those with #HAE. Learn more about our investigational treatment approach for #HAE here: https://bit.ly/4giCxVP This post relates to ongoing investigational studies. Safety and efficacy have not been established and approval is not guaranteed.

Welcome, Chris Wilson, as Pharvaris’ new Vice President, Sales and Marketing for North America. Throughout his career, Chris has led high-impact teams, strengthened launch preparedness, and shaped commercial strategies that prioritize the needs of healthcare providers and patients. His focus on culture, innovation, and execution has consistently expanded treatment possibilities for people living with rare conditions. At Pharvaris, Chris will work relentlessly to address current unmet needs and pursue solutions that provide people living with HAE greater control over their disease. Please join us in welcoming Chris to #Pharvaris! #HereditaryAngioedema #NewHire #DrugDevelopment #HAE

The past six months have been busy for the #PharvarisMedicalAffairs team led by Giorgio Giannattasio, MD, PhD. Podium presentations and posters were presented at medical meetings highlighting the potential of #deucrictibant as a #prophylactic and #OnDemand treatment for #HereditaryAngioedema. We want to make significant advances in the treatment of #HAE by listening carefully to the needs of the #HAECommunity. With these promising data and community insights, we are excited to continue the clinical development of deucrictibant. Learn more: https://bit.ly/4fPmhLe.

Our CEO, Berndt Modig connected with Amy Brown of BiotechTV about how we are advancing our investigational treatment, #deucrictibant, to help meet unmet needs of the #HereditaryAngioedema (#HAE) community. Learn more about our heritage and scientific approach by watching the full interview using the link below.

November is #NationalFamilyCaregiversMonth. Thank you to all caregivers who go above and beyond for those living with #HAE. For additional support, visit Hereditary Angioedema Association - HAEA for resources on navigating and managing life with #HAE: https://bit.ly/3V0O4kc

#Pharvaris is hiring. Are you looking for a place where your passion, knowledge and enthusiasm for #ClinicalTrials can make an impact? Pharvaris might be the company for you. We are seeking a seasoned #ClinicalTrialsManager to join our growing global #ClinicalOperationsTeam. In this #remote role, you will be supporting Christoph Cirillo, Bagya Syndraram and Stephani Thompson, PharmD, MS and will be responsible for the strategic oversight, management and delivery of our clinical trials program. We are looking for somebody with passion and a desire to make a real difference in the lives of people affected by #HereditaryAngioedema (HAE), a rare and potentially life-threatening genetic disease. Visit https://lnkd.in/d3zgSkK for more information and to #apply.

We shared Q3 #FinancialResults and business updates. This quarter, long-term extension data were presented on the potential of our investigational therapy #deucrictibant, highlighting its differentiated profile in the prevention and treatment of #HAE attacks. Initiation of CHAPTER-3 clinical study is expected by year-end and the ongoing enrollment of RAPIDe-3 clinical study is progressing. We also announced intent to expand clinical development of deucrictibant for the treatment of #AcquiredAngioedema due to C1 inhibitor deficiency. We believe deucrictibant has the potential to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral administration. Read more in our press release: https://bit.ly/4fn0j2z

Our Chief Medical Officer, Peng Lu, M.D., Ph.D., recently connected with Richard Gawel of Healio. Read the article to learn more about our data presented at #ACAAI24 and how #deucrictibant has the potential to offer injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy for #HereditaryAngioedema (#HAE): https://bit.ly/3NUI748

Muy honrada y agradecida por haber participado junto a mi equipo, del Meeting de investigadores de Pharvaris en Cartagena . Un evento de gran nivel que logró unir camaradería y ciencia. Me sentí muy bienvenida y entusiasmada de participar en el desarrollo de esta innovadora investigación que sin dudas mejorará la calidad de vida de nuestros pacientes con HAE. Fueron días intensos de compartir con colegas de Colombia, Brasil y Argentina con sus respectivos equipos. Pharvaris Eivind Omli Olga Uñate Peng Lu Ming Yu, MD, PhD Joan Mendivil Ricardo Zwiener Margarita Olivares Dra Anete Grumach I am very honored and grateful to have participated with my team in the Pharvaris researchers meeting in Cartagena. It was a high-level event that successfully combined camaraderie and science. I felt very welcomed and excited to be part of this innovative research, which will undoubtedly improve the quality of life for our patients with HAE. It was an intense few days of sharing with colleagues from Colombia, Brazil, and Argentina, along with their respective teams.